Filtered By:
Condition: Atrial Fibrillation
Drug: Coumadin
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 2924 results found since Jan 2013.
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
CONCLUSIONS: Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.PMID:37042255 | DOI:10.1161/CIRCULATIONAHA.122.062752
Source: Circulation - April 12, 2023 Category: Cardiology Authors: Josephine Harrington Anthony P Carnicelli Kaiyuan Hua Lars Wallentin Manesh R Patel Stefan H Hohnloser Robert P Giugliano Keith A A Fox Ziad Hijazi Renato D Lopes Sean D Pokorney Hwanhee Hong Christopher B Granger Source Type: research
Dabigatran Dosing Proposal for Adults with Atrial Fibrillation: Stress-testing Renal Function Range in Real World Patients
Clin Pharmacol Ther. 2023 Apr 7. doi: 10.1002/cpt.2902. Online ahead of print.ABSTRACTDabigatran is the first of four direct-acting oral anticoagulants approved to prevent stroke in adult patients with atrial fibrillation using a fixed 2-dose scheme compared to warfarin dosing adjusted to a prothrombin time range associated with optimal risk reduction in stroke and serious bleeding. The pivotal phase 3 trial found dabigatran, depending on dose, is superior to warfarin in stroke reduction and similar in bleeding risk while also showing dabigatran efficacy and safety correlate with steady-state plasma concentrations. Since t...
Source: Clinical Pharmacology and Therapeutics - April 7, 2023 Category: Drugs & Pharmacology Authors: J Robert Powell Farah Al Qaraghuli Jill Fiedler-Kelly Daniel Gonzalez Daniel Weiner Source Type: research
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Significant Mitral Stenosis —a Preliminary Meta-Analysis
ConclusionsDOACs were similar to warfarin in the efficacy and safety profiles in patients with AF and concomitant significant MS. Future evidence is expected from other large trials.
Source: Cardiovascular Drugs and Therapy - April 4, 2023 Category: Cardiology Source Type: research
Race, ethnicity, sex, and socioeconomic disparities in anticoagulation for atrial fibrillation: A narrative review of contemporary literature
J Natl Med Assoc. 2023 Mar 5:S0027-9684(23)00034-2. doi: 10.1016/j.jnma.2023.02.008. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most prevalent arrhythmia in the United States and is responsible for 1 in 7 ischemic strokes. While anticoagulation is effective at preventing strokes, prior work has highlighted significant disparities in anticoagulation prescribing. Furthermore, racial, ethnic, sex, and socioeconomic disparities in AF outcomes have been described. As such, we aimed to review recent data on disparities with respect to anticoagulation for AF published between January 2018 and February 2021. The...
Source: Journal of the National Medical Association - March 7, 2023 Category: General Medicine Authors: Danielle J Daly Utibe R Essien Marcela G Del Carmen Benjamin Scirica Adam N Berman Jennifer Searl Como Jason H Wasfy Source Type: research
Direct Oral Anticoagulants Versus Vitamin K Antagonist (Warfarin) For Stroke Prevention In Frail Patients With Atrial Fibrillation: A Meta-Analysis
Proc (Bayl Univ Med Cent). 2022 Dec 22;36(2):274-275. doi: 10.1080/08998280.2022.2155926. eCollection 2023.NO ABSTRACTPMID:36876251 | PMC:PMC9980567 | DOI:10.1080/08998280.2022.2155926
Source: Baylor University Medical Center Proceedings - March 6, 2023 Category: Universities & Medical Training Authors: Rupak Desai Aobo Li Avilash Mondal Priya Shenwai Bhavyasri Merugu Frailyn J Nunez Guzman Akhil Jain Source Type: research
